Explore
Validate
LearnMAB726-100
antibody from R&D Systems
Targeting: TNFRSF1B
CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB726-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TNF RII/TNFRSF1B Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human TNF RII in ELISAs and Western blots. In ELISAs, no cross-reactivity or interference was observed with recombinant human (rh) TNF RI, recombinant mouse (rm) TNF RI, rmTNF RII, rmTNF-alpha , rhTNF-alpha , or rhTNF-beta . In Western blots, this antibody does not cross-react with rhTNF RI, rmTNF RI, or rmTNF RII.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
P20333- Isotype
- IgG
- Antibody clone number
- 22210
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells.
Direct comparison of traditional ELISAs and membrane protein arrays for detection and quantification of human cytokines.
A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.
Rossol M, Meusch U, Pierer M, Kaltenhäuser S, Häntzschel H, Hauschildt S, Wagner U
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 15;179(6):4239-48
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 15;179(6):4239-48
Direct comparison of traditional ELISAs and membrane protein arrays for detection and quantification of human cytokines.
Copeland S, Siddiqui J, Remick D
Journal of immunological methods 2004 Jan;284(1-2):99-106
Journal of immunological methods 2004 Jan;284(1-2):99-106
A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.
Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD
The American journal of gastroenterology 2000 Sep;95(9):2338-42
The American journal of gastroenterology 2000 Sep;95(9):2338-42
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TNF RII/TNFRSF1B Inhibition of TNF-alpha-induced Cytotoxicity and Neutralization by Human TNF RII/TNFRSF1B Antibody. Recombinant Human TNF RII/TNFRSF1B Fc Chimera (Catalog # 726-R2) inhibits Recombinant Human TNF-alpha (Catalog # 210-TA) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of Recombinant Human TNF-alpha (0.25 ng/mL) activity elicited by Recombinant Human TNF RII/TNFRSF1B Fc Chimera (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB726). The ND50 is typically 0.5-1.5 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL).
